Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2017 (pdf):
download in single page format - double page (broad) format

Publication overview

Current news and events

Successful kick-off for new collaboration between Institute for Cancer Research and Institut Curie

Cancer researchers from Institute for Cancer Research, Oslo, and Institut Curie, Paris, held a successful kick-off seminar in Paris on March 25th, followed by a reception with Norway’s ambassador in France.

Thanks to a generous donation from Trond S. Paulsen, a new collaboration between ICR and Institut Curie, Paris, was opened. The funded project, “Mechanisms of cancer cell invasion” (InvaCell), is a collaboration between the groups of Harald Stenmark, ICR, and Philippe Chavrier, Institut Curie.

Protonics team leader presenting their research on The Scientist's Channel

Dr. Theodossis Theodossiou discusses his team’s cutting-edge research into curing cancer with photodynamic therapy (PDT). PDT is an exciting anti-cancer treatment, currently used clinically. It works by using light, a photo-activatable drug and oxygen to kill cancer. With the specificity of the treatment relying on the application of light.

In this video, Dr. Theodossiou describes how his team are working to improve the efficiency and accuracy of PDT through a variety of methods.

Maria Torgersen and coworkers publish unexpected results about nanoparticle effects on cells

Maria Torgersen, senior author

The article entitled “Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death”, just published in Nanotoxicology, describes details about the toxic mechanisms obtained by testing three very similar nanoparticles on six cancer cell lines. The three different types of particles where all of the class poly(alkylcyanoacrylate), they differed only in their alkyl side chains being butyl (PBCA), ethylbutyl (PEBCA) or octyl (POCA). Such substances have for many years been used as medical glue. The authors describe different effects of these nanoparticles.

Units and subpages

View all subunitsHide all subunits